title: The effect of argatroban on injured endothelial cells by thrombin.
abstract: When endothelial cells are exposed to thrombin, they become perturbed and acquire thrombogenic properties. Argatroban is an arginine derivative, synthetic small molecule that binds to the active site of thrombin and inhibits its catalytic activity. Therefore, the effects of argatroban on endothelial cells, which had been injured by thrombin, were investigated. The established endothelial cell line, TKM-33, which had been cloned from human umbilical vein endothelial cells, was used. Endothelial cells produce plasminogen activator (PA) to prevent thrombosis and maintain the blood flow. When the endothelial cells were injured by thrombin, secretion of plasminogen activator inhibitor-1 (PAI-1) increased and then the PA activity proportionally decreased. The treatment of endothelial cells with argatroban after thrombin injury did not restore their reduced PA activity. However, the treatment of endothelial cells with argatroban prior to thrombin injury resulted in inhibiting the induction of PAI-1 secretion. Thus, pretreatment of endothelial cells with argatroban suppresses the inhibition of their PA activity by thrombin. Since the effect of thrombolytic agent may be modified by the fibrinolytic factors produced by the endothelial cells, the activity of staphylokinase (SAK) was measured in the presence of endothelial cells that had been injured by thrombin. SAK is a newly developed thrombolytic agent. SAK activity in the presence of injured endothelial cells by thrombin was lower than that in the presence of endothelial cells without thrombin injury. However, treatment of endothelial cells with argatroban prior to thrombin injury revealed higher SAK activity than that after thrombin injury. These findings indicate that argatroban pretreatment prevents thrombin injury of endothelial cells, which may then maintain their physiological function.
authors.affiliation: Department of Physiology, Kinki University School of Medicine, Ohnohigashi, Osakasayama, Japan. sueshima@med.kindai.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Ueshima
authors.forename: H
authors.initials: H
authors.lastname: Fukao
authors.forename: K
authors.initials: K
authors.lastname: Okada
authors.forename: O
authors.initials: O
authors.lastname: Matsuo
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives; D002460:Cell Line; D017077:Culture Media, Conditioned / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006490:Hemostatics / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D010875:Pipecolic Acids / Q000378:metabolism / Q000494:pharmacology*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010960:Plasminogen Activators / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects / Q000378:metabolism; D013449:Sulfonamides; D013917:Thrombin / Q000494:pharmacology*
chemical_list: D017077:Culture Media, Conditioned; D006490:Hemostatics; D010875:Pipecolic Acids; D017395:Plasminogen Activator Inhibitor 1; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D001120:Arginine; D010960:Plasminogen Activators; D013917:Thrombin; C031942:argatroban